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ABSTRACT
Objective: To identify factors that determine disease severity and clinical phenotype of the most
common spinocerebellar ataxias (SCAs), we studied 526 patients with SCA1, SCA2, SCA3. or
SCA6.
Methods: To measure the severity of ataxia we used the Scale for the Assessment and Rating of
Ataxia (SARA). In addition, nonataxia symptoms were assessed with the Inventory of Non-Ataxia
Symptoms (INAS). The INAS count denotes the number of nonataxia symptoms in each patient.
Results: An analysis of covariance with SARA score as dependent variable and repeat lengths of
the expanded and normal allele, age at onset, and disease duration as independent variables led
to multivariate models that explained 60.4% of the SARA score variance in SCA1, 45.4% in
SCA2, 46.8% in SCA3, and 33.7% in SCA6. In SCA1, SCA2, and SCA3, SARA was mainly
determined by repeat length of the expanded allele, age at onset, and disease duration. The only
factors determining the SARA score in SCA6 were age at onset and disease duration. The INAS
count was 5.0! 2.3 in SCA1, 4.6! 2.2 in SCA2, 5.2! 2.5 in SCA3, and 2.0! 1.7 in SCA6. In
SCA1, SCA2, and SCA3, SARA score and disease duration were the strongest predictors of the
INAS count. In SCA6, only age at onset and disease duration had an effect on the INAS count.
Conclusions: Our study suggests that spinocerebellar ataxia (SCA) 1, SCA2, and SCA3 share a
number of common biologic properties, whereas SCA6 is distinct in that its phenotype is more
determined by age than by disease-related factors. Neurology® 2008;71:982–989
GLOSSARY
INAS" Inventory of Non-Ataxia Symptoms; SARA" Scale for the Assessment and Rating of Ataxia; SCA" spinocerebellar
ataxia.
The spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of
autosomal dominantly inherited progressive ataxia disorders. Up to now, more than 25 differ-
ent gene loci have been found. In more than 10 SCAs, the affected genes and causative muta-
tions have been identified. The most common SCAs, which together account for more than
half of all affected families, are SCA1, SCA2, SCA3, and SCA6. Each of these disorders is
caused by a translated CAG repeat expansion mutation.1-6 Expanded CAG repeats are dynamic
mutations with variable length that may change during transmission. Patients with longer
repeats have an earlier disease onset, a more severe phenotype, and faster disease progression
than patients with shorter repeats.7-9
In all SCAs, ataxia is the predominant clinical manifestation. Nevertheless, patients may
present with additional nonataxia symptoms. SCA1, SCA2, and SCA3 are characterized by the
appearance of such additional symptoms.10-16 SCA6, on the other hand, is considered an almost
purely cerebellar disorder. SCA6 is also different in that it begins between the age of 50 to 60
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years while most other SCAs including SCA1,
SCA2, and SCA3 have an onset between 30
and 40 years.17,18
Although there are numerous studies that de-
scribe clinical manifestations of SCA1, SCA2,
SCA3, and SCA6, knowledge of the factors that
determine disease severity and clinical pheno-
type of SCAs is limited. This is because large
comparative studies using validated clinical out-
come measures are lacking. We therefore per-
formed a multicenter study that included 526
patients with SCA1, SCA2, SCA3, or SCA6. All
patients underwent a standardized clinical evalu-
ation using scales that measure severity of ataxia
and presence of nonataxia symptoms. We were
particularly interested to learn how repeat
length, age at onset, and disease duration affect
severity of ataxia and appearance of nonataxia
symptoms.
METHODS The study was performed at 17 European centers
which together form the EUROSCA clinical group. Patients
were eligible when they had progressive, otherwise unexplained
ataxia and a positive molecular genetic test for SCA1, SCA2,
SCA3, or SCA6. Cases were ascertained with the help of an
electronic patient registry that contains data of all SCA patients
that have been in contact with one of the study centers. Patients
were consecutively recruited within a predetermined period be-
tween July 2005 and August 2006. The study population con-
sisted of 526 patients (SCA1: 117, SCA2: 163, SCA3: 139,
SCA6: 107).
Assessments were done according to a written study proto-
col. There were maximally three investigators at each center. All
investigators were experienced in the use of the applied scales.
To measure the severity of ataxia we used the Scale for the
Assessment and Rating of Ataxia (SARA) that has been recently
developed and validated.19 The SARA sum score ranges from 0
to 40 with 0 indicating absence of ataxia and 40 the most severe
degree of ataxia.
Nonataxia symptoms were assessed with the Inventory of
Non-Ataxia Symptoms (INAS). INAS consists of 30 items, each
of which is related to one of the following 16 symptoms or syn-
dromes: areflexia, hyperreflexia, extensor plantar response, spas-
ticity, paresis, amyotrophy, fasciculations, myoclonus, rigidity,
chorea, dystonia, resting tremor, sensory symptoms, brainstem
oculomotor signs (horizontal and vertical ophthalmoparesis,
slowing of saccades), urinary dysfunction, and cognitive impair-
ment. In this study, only the presence or absence of one of these
symptoms was considered. When several INAS items were re-
lated to one symptom, the symptom was recorded as present if at
least one item was positive. The number of nonataxia symptoms
was counted in each patient, yielding the INAS count, a dimension-
less value with a range from 0 to 16. Reliability of INAS ratings was
previously tested in two clinical trials that served to validate SARA.
For most INAS items, it was found to be acceptable.
In 450 of the 526 study participants, DNA samples were
available. In these samples, repeat lengths of the expanded and
normal alleles were determined at the Department of Human
Genetics of the University of Tu¨bingen. In 53 participants, in-
formation about repeat lengths was taken from medical records.
In the remaining 23 participants, information on repeat length
was lacking.
Statistical analyses were performed with SAS 8 software (SAS
Institute, Cary, NC). Test results were considered significant at
the 0.05 level. Patient clinical characteristics were compared
among SCA groups with an analysis of variance for continuous
variables and with a !2 test for categorical variables. Associations
between the SARA score and covariates were tested using Pear-
son correlation test for continuous variables and univariate anal-
ysis of variance for categorical variables. For each SCA group, an
analysis of covariance was performed with SARA score as depen-
dent variable and gender, repeat lengths of the expanded and
normal allele, age at onset, and disease duration as independent
variables. The model was adjusted on family and center effect,
and simple interactions were included. Effects were removed in
descending significance, until all remaining effects were signifi-
cant at the 0.05 level (backward selection). Relationships be-
tween nonataxia symptoms and clinical characteristics were
studied using univariate logistic regressions with Bonferroni cor-
rection. For each SCA type, modeling of INAS count was per-
formed with an analysis of covariance. As for SARA modeling,
independent effects were backward selected.
The study was approved by the ethics committees of the
contributing centers. Informed and written consent was ob-
tained from all study participants.
RESULTS Patients. Demographic and clinical data
of the study population are given in table 1. The
patients with SCA1 (n " 117) came from 90 fami-
lies, the SCA2 (n " 163) from 103, the SCA3 (n "
139) from 107, and the SCA6 (n " 107) from 81.
Age and age at onset were similar in SCA1 (age: 46.3 !
12.2 years; age at onset: 37.0 ! 10.6 years), SCA2
(age: 46.3 ! 13.3 years; age at onset: 34.9 ! 12.7
years), and SCA3 (age: 48.8 ! 11.8 years; age at
onset: 37.1! 11.4 years), but considerably higher in
SCA6 (age: 64.9 ! 11.0 years; age at onset: 54.5 !
10.2 years). In contrast, disease duration was in the
same range in all groups (SCA1: 9.5 ! 5.5 years;
SCA2: 11.3 ! 6.5 years; SCA3: 11.6 ! 5.9 years;
SCA6: 10.4 ! 6.4 years).
Ataxia. Disease severity, as indicated by the SARA
score, was similar in all groups (SCA1: 15.6 ! 9.1;
SCA2: 15.8 ! 8.0; SCA3: 15.1 ! 8.6; SCA6: 15.0 !
6.7) (table 1). The SARA score increased with repeat
length of the expanded allele in SCA2 and SCA3, but
not in SCA1 and SCA6. There was no correlation
between SARA and repeat length of the normal allele
in any of the groups. In SCA1 and SCA6, but not in
SCA2 and SCA3, SARA increased with age. In
SCA2, but not in the other SCA disorders, SARA
was greater in patients with earlier disease onset. In
all groups, the SARA score increased with disease du-
ration (table 2). Inspection of the correlation curves
showed that the increase of the SARA score over time
was faster in SCA1 than in the other groups. This
was confirmed by an analysis of covariance that re-
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vealed an interaction between SCA type and disease
duration (p # 0.001).
An analysis of covariance with SARA score as de-
pendent variable and gender, repeat lengths of the
expanded and normal allele, age at onset, and disease
duration as independent variables led to multivariate
models of SARA that explained 60.4% of the vari-
ance in SCA1, 45.4% in SCA2, 46.8% in SCA3, and
33.7% in SCA6. The estimates and p values of the
respective values are given in table e-1 on the Neurology®
Web site at www.neurology.org. In none of the
groups did gender have an effect on the SARA score.
Age was not included in the model, as it is the sum of
age at onset and disease duration.
The multivariate models predicting the SARA
score in SCA1, SCA2, and SCA3 were quite similar.
SARA was mainly determined by disease duration,
age at onset, and repeat length of the expanded allele.
In all three disorders, there were positive interactions
between disease duration and age at onset as well as
disease duration and repeat length of the expanded
allele indicating an increase of the SARA score with
each of these factors. Repeat length of the normal
allele was included only in the SCA1 model. The
negative estimate of the interaction between the re-
peat length of the expanded and normal allele indi-
cates that the disease is most severe with long
expanded and short normal alleles (table e-1). The
effect of the repeat lengths on the SARA score in
SCA1 is illustrated in the figure. In this example, age
at onset (37 years) and disease duration (9 years)
were set at the median values of the SCA1 group.
The only factors determining the SARA score in
SCA6 were age at onset and disease duration. Higher
age at onset and longer disease duration predicted
more severe ataxia (table e-1).
Nonataxia symptoms. The distribution of nonataxia
symptoms among the groups was uneven (table 3).
Pyramidal tract signs were most frequent in SCA1,
Table 1 Demographic, genetic, and clinical characteristics of the study population
SCA1 SCA2 SCA3 SCA6
No. 117 163 139 107
No. of families 90 103 107 81
M/F 71/46 75/88 73/66 58/49
Repeat length expanded allele 47.4! 5.2 (39–66) 39.3! 3.2 (33–52) 68.8! 4.6 (56–91) 22.4! 0.9 (21–28)
Repeat length normal allele 28.9! 1.7 (22–36) 22.2! 1.4 (14–33) 21.7! 5.0 (14–35) 12.6! 1.1 (8–16)
Age, y 46.3! 12.2 (18–76) 46.3! 13.3 (18–84) 48.8! 11.8 (14–81) 64.9! 11.0 (37–85)
Age at onset, y 37.0! 10.6 (15–65) 34.9! 12.7 (7–66) 37.1! 11.4 (5–66) 54.5! 10.2 (31–77)
Disease duration, y 9.5! 5.5 (1–28) 11.3! 6.5 (0–40) 11.6! 5.9 (1–28) 10.4! 6.4 (1–33)
SARA 15.6! 9.1 (2–40) 15.8! 8.0 (2–39) 15.1! 8.6 (1–40) 15.0! 6.7 (1–33)
INAS count 5.0! 2.3 (0–11) 4.6! 2.2 (0–13) 5.2! 2.5 (0–12) 2.0! 1.7 (0–9)
If applicable, values are given as mean! SD (range).
SCA " spinocerebellar ataxia; SARA " Scale for the Assessment and Rating of Ataxia; INAS " Inventory of Non-Ataxia
Symptoms.
Table 2 Correlation of the SARA score and the INAS count with repeat lengths of expanded and normal
allele, age, age at onset, disease duration, and among SARA and INAS
SCA1 SCA2 SCA3 SCA6
SARA INAS SARA INAS SARA INAS SARA INAS
Repeat length expanded
allele
NS NS 0.38 0.38 0.35 0.31 NS NS
Repeat length normal allele NS NS NS NS NS NS NS NS
Age, y 0.28* NS NS $0.23* NS NS 0.38 0.31
Age at onset, y NS NS $0.28 $0.31 NS $0.29 NS NS
Disease duration, y 0.65 0.39 0.39 0.16† 0.49 0.40 0.53 0.38
SARA — 0.62 — 0.61 — 0.61 — NS
Correlation coefficients are given. All p values were#0.001, unless otherwise stated.
*p# 0.01, †p# 0.05.
SARA"Scale for theAssessment andRating of Ataxia; INAS" Inventory of Non-Ataxia Symptoms; SCA" spinocerebellar
ataxia; NS" not significant.
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whereas motor symptoms indicating peripheral nerve
involvement were most frequent in SCA2. Myoclo-
nus, rigidity, chorea/dyskinesia, dystonia, and resting
tremor were rare in all groups with the exception of
dystonia, which was found in 23.9% of all patients
with SCA3.
To identify factors that determine the occurrence
of specific nonataxia symptoms we performed a lo-
gistic regression for each symptom with repeat length
of the expanded allele, age at onset, age, disease dura-
tion, and SARA score as independent variables. For
SCA1, this analysis showed that higher age was asso-
ciated with urinary dysfunction and cognitive im-
pairment. In SCA2, longer repeats and earlier age at
onset increased the likelihood of muscle atrophy and
brainstem oculomotor signs. Longer repeats were
further associated with chorea/dyskinesia and dysto-
nia. In SCA3, larger repeats and earlier age at onset
were associated with spasticity and hyperreflexia. In
contrast, motor symptoms indicating peripheral
nerve involvement in SCA3 were more likely with
higher age at onset, higher age, and longer disease
duration. In SCA6, the likelihood of a number of
symptoms increased with age at onset, disease dura-
tion, and age. Higher SARA score increased the risks
of various nonataxia symptoms in all four diseases. A
list of those symptoms that were significantly af-
fected by repeat length, age at onset, age, or disease
duration is given in table 4.
The INAS count, which is a measure of noncer-
ebellar involvement, was similar in SCA1 (5.0 !
2.3), SCA2 (4.6 ! 2.2), and SCA3 (5.2 ! 2.5) and
considerably lower in SCA6 (2.0 ! 1.7) (table 1).
The INAS count increased with disease duration in
all groups, and with SARA in SCA1, SCA2, and
SCA3. In SCA2 and SCA3, the INAS count in-
creased with repeat length of the expanded allele and
decreased with age at onset (table 2).
An analysis of covariance with the INAS score as
dependent variable and repeat length of the ex-
panded allele, age at onset, and disease duration as
independent variables led to multivariate models of
INAS that explained only 15.2% (SCA1) to 41.2%
(SCA6) of the variance. When SARA was included,
this value increased to 43.1% in SCA1, 48.3% in
SCA2, and 57.5% in SCA3, whereas SARA was no
significant predictor for the INAS count in SCA6.
The strongest predictors of the INAS count in SCA1,
SCA2, and SCA3 were SARA score and disease dura-
tion. In SCA6, only age at onset and disease duration
had an effect on INAS count (table e-2).
DISCUSSION This study provides a comprehensive
and quantitative account of the clinical phenotypes
and their determining factors of the four most com-
mon SCAs: SCA1, SCA2, SCA3, and SCA6. The
analysis is based on a cross-sectional examination of
526 patients with SCA using standardized and vali-
dated clinical assessment instruments.
To assess disease severity we used the newly devel-
oped SARA scale that is based on a semiquantitative
assessment of cerebellar ataxia on an impairment
level. SARA underwent a rigorous validation proce-
dure involving three clinical trials in large groups of
patients with SCA and non-SCA ataxia, and con-
trols. Although the cerebellum is directly involved in
the coordination of eye movements, oculomotor
functions are not considered in SARA as the validation
trials indicated that they are determined by other factors
than appendicular and midline ataxia.19,20
The present data allowed calculating genotype-
specific multivariate models that predicted the SARA
score with considerable accuracy. The part of the
variance that was explained ranged from 33.7% in
SCA6 to 60.4% in SCA1. In accordance with the
Figure Graphical display of the effects of the
repeat lengths of the expanded and
normal alleles on the SARA score in
SCA1
Family and center were entered in the model as random ef-
fect. TheSARAvaluespredictedby themultivariatemodel are
depicted by the colored bars. For this example, age at onset
(37 years) and disease duration (9 years) were set at the me-
dian values of theSCA1group. SARA"Scale for theAssess-
ment andRating of Ataxia; SCA" spinocerebellar ataxia.
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progressive course of these diseases, disease duration
was positively correlated with SARA score in the uni-
variate analysis and a strong predictor of the SARA
score in the multivariate models of all groups. A
comparison of the regression curves revealed that
progression was fastest in SCA1 and somewhat
slower in SCA2, SCA3, and SCA6. This is in line
with clinical observations suggesting that SCA1 often
takes a more aggressive course than other SCAs.
Moreover, a study using retrospective assessment of
disease stages found a faster progression in SCA1
compared to SCA2, SCA3, and dominant ataxias
with a purely cerebellar phenotype.9 Nevertheless, re-
sults of prospective studies are required to obtain
quantitative and reliable information on disease pro-
gression in the various SCAs.
In the SCA6 model, age at onset was the only
factor other than disease duration that contributed to
the SARA score. This is in line with the univariate
analysis where the SARA score was positively corre-
lated with age and disease duration. This suggests
that disease severity in SCA6 is mainly age-
dependent. However, compared to the models for
SCA1, SCA2, and SCA3, the SCA6 model explained
a much smaller part of the observed variance, sug-
gesting that individual factors other than those in-
cluded in the present model strongly contribute to
disease severity in SCA6.
The models for SCA1, SCA2, and SCA3 were
more complex than that for SCA6 and shared a num-
ber of common properties, the most important of
which was the effect of the repeat length of the ex-
panded allele. Although expected, this is a new find-
ing as previous studies focused on the effect of repeat
length on age at onset and rate of disease progres-
sion.7,9 SCA1 had the unusual feature that the repeat
length of the normal allele had an influence on the
disease severity. According to the model, SCA1 is
most severe with long expanded and short normal
alleles. Interestingly, smaller normal alleles were pre-
viously found to be associated with earlier disease on-
set in SCA1.7 The results of both studies thus point
to the same “paradoxical” association of smaller nor-
mal alleles with a more severe phenotype in SCA.
Although ataxia is the prominent symptom of all
SCAs, there are various neurologic symptoms that
may accompany ataxia. Reliable and quantitative as-
sessment of these symptoms is likewise important
and difficult as the variable symptoms may contrib-
ute to disability but on the other hand require appli-
cation of numerous different clinical scales. To
escape this dilemma we devised INAS, a list of neuro-
logic symptoms that allows determining the presence or
absence of 16 nonataxia symptoms in a reliable and
standardized way. By counting the number of nona-
taxia symptoms in each patient, INAS yields a simple
quantitative measure of noncerebellar involvement.
The present data on the distribution and fre-
quency of nonataxia symptoms in SCA1, SCA2,
SCA3, and SCA6 confirm and extend the results of
numerous previous studies.10-18 Our data show that
SCA6 is not a purely cerebellar disorder in a strict
Table 3 Frequency of nonataxia symptoms
SCA1 SCA2 SCA3 SCA6 p
Hyperreflexia 67.5 13.2 40.1 21.9 #0.001
Areflexia 17.9 64.4 57.8 23.8 #0.001
Extensor plantar 50.5 31.0 41.9 2.0 #0.001
Spasticity 59.3 8.9 44.4 13.6 #0.001
Paresis 22.4 14.4 24.8 5.7 #0.001
Muscle atrophy 29.1 22.5 39.0 10.7 #0.001
Fasciculations 39.1 38.3 37.0 2.8 #0.001
Myoclonus 4.3 13.7 4.4 0.0 #0.001
Rigidity 1.7 7.4 10.3 5.7 NS
Chorea/dyskinesia 6.8 6.8 10.1 1.9 NS
Dystonia 12.8 14.2 23.9 4.7 #0.001
Resting tremor 6.8 14.9 3.6 1.9 #0.001
Sensory symptoms 62.4 68.4 65.6 48.0 NS
Urinary dysfunction 35.0 40.4 45.6 31.1 NS
Cognitive impairment 21.5 25.9 19.3 10.5 NS
Brainstem oculomotor signs 74.1 87.0 67.9 25.2 #0.001
Values are percentages. After Bonferroni correction, only p values#0.0031 were considered significant.
SCA" spinocerebellar ataxia; NS" not significant.
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neurologic sense. On average, each patient with
SCA6 had two nonataxia symptoms.
To identify factors that determine the occurrence
of nonataxia symptoms in SCA1, SCA2, SCA3, and
SCA6, we performed univariate analyses that re-
vealed patterns of symptoms and factors that were
specific for each SCA. In SCA1, higher age was asso-
ciated with urinary dysfunction and cognitive im-
pairment. In SCA2, long expanded repeats and early
age at onset increased the likelihood of brainstem oc-
ulomotor signs, muscle atrophy, and hyperkinetic
movement disorders. The dependence of brainstem
oculomotor signs on repeat length was expected as a
previous oculographic study found that saccades
were slower in patients with SCA2 with longer re-
peats.21 The phenotypic variability in SCA3 has been
attributed to differences in repeat length of the ex-
panded allele. Large expanded alleles have been
found in patients with early disease onset and
marked pyramidal and extrapyramidal features,
whereas those with prominent ataxia and ophthal-
moplegia and patients with late disease onset and
marked peripheral involvement had smaller expan-
sions.8 These results are partly confirmed by the
present study. Indeed, larger repeats and earlier age at
onset were associated with spasticity and hyperreflexia.
On the other hand, our data suggest that the presence of
peripheral motor signs is age-dependent and not influ-
enced by repeat length. A previous nerve conduction
study came to a similar conclusion. According to that
study, the degree of peripheral damage in SCA3 did not
depend on repeat length, but rather on age.22
In SCA1, SCA2, and SCA3, SARA score and dis-
ease duration were the strongest predictors of the
Table 4 Logistic regression of each nonataxia symptomwith repeat length of the expanded allele, age at
onset, age, and disease duration as independent variables
Genotype Factor Symptom OR (95%) p
SCA1 Age Urinary dysfunction 1.046 (1.016–1.078) 0.0030
Cognitive impairment 1.060 (1.024–1.096) 0.0010
SCA2 Repeat length expanded allele Muscle atrophy 1.232 (1.105–1.374) #0.001
Chorea/dyskinesia 1.242 (1.075–1.434) 0.0030
Dystonia 1.216 (1.093–1.353) #0.001
Brainstem oculomotor signs 1.764 (1.309–2.377) #0.001
Age at onset Muscle atrophy 0.933 (0.902–0.966) #0.0001
Brainstem oculomotor signs 0.922 (0.892–0.954) #0.0001
SCA3 Repeat length expanded allele Hyperreflexia 1.210 (1.075–1.362) 0.0020
Spasticity 1.333 (1.152–1.543) #0.001
Brainstem oculomotor signs 1.126 (1.034–1.226) 0.006
Age at onset Hyperreflexia 0.935 (0.901–0.971) 0.0005
Areflexia 1.085 (1.033–1.139) 0.0011
Spasticity 0.869 (0.827–0.914) #0.0001
Age Hyperreflexia 0.930 (0.900–0.961) #0.0001
Areflexia 1.137 (1.067–1.212) #0.0001
Spasticity 0.886 (0.847–0.927) #0.0001
Muscle atrophy 1.045 (1.016–1.075) 0.0020
Disease duration Areflexia 1.118 (1.046–1.195) 0.0011
Muscle atrophy 1.105 (1.035–1.179) 0.0026
Urinary dysfunction 1.104 (1.037–1.175) 0.0020
Brainstem oculomotor signs 1.126 (1.041–1.217) 0.0029
SCA6 Age at onset Chorea/dyskinesia 1.129 (1.078–1.182) #0.0001
Age Chorea/dyskinesia 1.170 (1.076–1.272) 0.0002
Resting tremor 1.069 (1.023–1.117) 0.0029
Disease duration Areflexia 1.132 (1.051–1.219) 0.0011
Extensor plantar 1.057 (1.020–1.096) 0.0024
Urinary dysfunction 1.150 (1.072–1.234) #0.0001
Only effects that were significant after Bonferroni correction (p# 0.0031) are shown.
OR" odds ratio; SCA" spinocerebellar ataxia.
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INAS count, i.e., the number of nonataxia symptoms
in each patient. In SCA6, only age at onset and dis-
ease duration contributed to the INAS count. Exclu-
sion of SARA—which is not a true independent
variable—from the calculation resulted in an insuffi-
cient predictive power of the models. These observa-
tions characterize the INAS count as a disease and
progression marker in SCA1, SCA2, and SCA3 that
is strongly related but not equal to SARA. As it cap-
tures other aspects than SARA, it might be useful as
an additional outcome measure in clinical studies.
However, the sensitivity of the INAS count to
change is currently unknown. The time- and age-
dependence of the INAS count in SCA6 raises the
question to which degree nonataxia symptoms in
SCA6 are due to the disease itself or rather a conse-
quence of aging.
Our data add further weight to the view that
SCA1, SCA2, and SCA3 share a number of biologic
properties whereas SCA6 is not only distinct in that
it starts later and has less nonataxia symptoms, but
also distinct in that its phenotype is more determined
by age than by disease-related factors. Our results are
of importance for the design of future interventional
trials, in particular for the stratification of patients.
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